RxDoctor Payments Data

Laura Sapaugh, PA

Physician Assistant · Fort Worth, TXNPI 1942501366

Payments from drug & device makers

$8,786in general payments, 2019–2025

Across 408 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$1K
  • Pfizer$814
  • AbbVie$742
  • Boehringer Ingelheim$634
  • Sanofi-aventis U.S. LLC$526
  • Novo Nordisk$463
  • plus $4K from 40 others

What the payments were for

  • Consulting fees$8009%
  • Travel & lodging$3043%
  • Food & beverage$7,57286%
  • Education$1101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,786 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$36,409
Medicare patients
144
Services billed
740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$84,424
MounjaroTirzepatide39$42,984
JardianceEmpagliflozin24$20,427
FarxigaDapagliflozin Propanediol14$12,716
KerendiaFinerenone12$12,588
Janumet XrSitagliptin Phos/Metformin Hcl21$11,827
Tresiba Flextouch U-100Insulin Degludec13$10,484
Breo ElliptaFluticasone/Vilanterol18$7,407
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,036
SynjardyEmpagliflozin/Metformin Hcl11$6,879
Gabapentin124$2,041
Solifenacin Succinate14$1,749
Atorvastatin Calcium177$1,682
Rosuvastatin Calcium116$1,546
Lisinopril152$1,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$463$84,42465 claims
Lilly USA, LLCMounjaro$291$42,98439 claims
Boehringer IngelheimJardiance, Synjardy$634$27,30635 claims
GSKBreo Ellipta, Trelegy Ellipta$188$14,44329 claims
AstraZenecaFarxiga$460$12,71614 claims
BayerKerendia$345$12,58812 claims
MerckJanumet Xr$47$11,82721 claims
AbbVieSynthroid$742$48911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →